Cited by 210Regulation of Appetite and ObesityAdipokines, Inflammation, and Metabolic DiseasesLipid metabolism and biosynthesis

Site and mechanism of leptin action in a rodent form of congenital lipodystrophy

Open access
Asilmaz, Esra, Cohen, Paul, Miyazaki, Makoto, Dobrzyn, Pawel, Ueki, Kohjiro, Fayzikhodjaeva, Gulnorakhon, Soukas, Alexander A., Kahn, C. Ronald +3 more·2004·Journal of Clinical Investigation

Abstract

Lipodystrophy is characterized by the complete or partial absence of adipose tissue, insulin resistance, hepatic steatosis, and leptin deficiency. Here, we show that low-dose central leptin corrects the insulin resistance and fatty liver of lipodystrophic aP2-nSREBP-1c mice, while the same dose given peripherally does not. Central leptin also repressed stearoyl-CoA desaturase-1 (SCD-1) RNA and enzymatic activity, which were increased in livers of lipodystrophic mice. aP2-nSREBP-1c mice homozygous for an SCD-1 deletion had markedly reduced hepatic steatosis, increased saturated fatty acids, decreased acetyl-CoA carboxylase activity, and decreased malonyl-CoA levels in the liver. Despite the reduction in hepatic steatosis, these mice remained diabetic. A leptin dose-response curve showed that subcutaneous leptin improved hyperglycemia and hyperinsulinemia in aP2-nSREBP-1c mice at doses that did not substantially alter hepatic steatosis or hepatic SCD enzymatic activity. Leptin treatment at this dose improved insulin-stimulated insulin receptor and insulin receptor substrate 2 (IRS-2) phosphorylation, IRS-2–associated PI3K activity, and Akt activity in liver. Together, these data suggest that CNS-mediated repression of SCD-1 contributes to leptin's antisteatotic actions. Intracerebroventricular leptin improves glucose homeostasis by improving insulin signal transduction in liver, but in this case the effect appears to be independent of SCD-1.

Integrity signals

Registry

Crossref · 10.1172/jci200419511

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Low-dose intracerebroventricular administration of leptin corrects the insulin resistance and diabetes phenotype of both leptin-deficient ob/ob and lipodystrophic mice.

    “low-dose i.c.v. administration of leptin corrects the insulin resistance and diabetes phenotype of both leptin deficient ob/ob and lipodystrophic mice (2).”
  • In rodent models, leptin increased expression of AMP-activated protein kinase and PPARα, activating enzymes of fatty acid oxidation and inhibiting enzymes of lipogenesis.

    “In rodent models, leptin increased expression of AMP-activated protein kinase (28) and peroxisome proliferator-activated receptor (PPAR) ␣ (29), activating enzymes of fatty acid oxidation, including carnitine palmitoyl transferase-1 and acyl-CoA oxidase, and inhibiting enzymes of lipogenesis, including acyl-CoA carboxylase and stearoyl-CoA desaturase-1 (28,30).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Asilmaz, E., Cohen, P., Miyazaki, M., Dobrzyn, P., Ueki, K., Fayzikhodjaeva, G., Soukas, A. A., Kahn, C. R., Ntambi, J. M., Socci, N. D., & Friedman, J. M.
Affiliations
  • Rockefeller University (US)
  • University of Wisconsin System (US)
  • Joslin Diabetes Center (US)
  • Albert Einstein College of Medicine (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
Friedman, Jeffrey M.
Venue
Journal of Clinical Investigation
Published
2004-02-01
Volume
113
Issue
3
Pages
414-424
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2104945088
Cited by
210
References
51
Citations by year
2025: 1 · 2024: 2 · 2023: 9 · 2022: 2 · 2021: 5 · 2020: 6 · 2019: 8 · 2018: 3 · 2017: 9 · 2016: 13 · 2015: 8 · 2014: 13 · 2013: 12 · 2012: 5
FWCI
6.74
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (GM07739, MSTPGM07739)
  • National Institute of General Medical Sciences (GM 07739, T32GM007739)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK-41096, R01DK062388, R01-DK-62388, R01DK041096)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
Keywords
leptin, congenital lipodystrophy, insulin resistance, hepatic steatosis, stearoyl-CoA desaturase 1, glucose homeostasis, insulin receptor substrate 2, PI3K/Akt signaling, acetyl-CoA carboxylase, malonyl-CoA
MeSH terms
Animals, Disease Models, Animal, Female, Lipodystrophy, Liver, Male, Mice, Inbred C57BL, Phylogeny, Stearoyl-CoA Desaturase, Muscle, Skeletal, Leptin, Gene Expression Profiling, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review